(Fighting the New Coronavirus) French pharmaceutical company Sanofi will assist in the production of Pfizer vaccines, and plans to provide 100 million doses of the EU this year. China News Service, Paris, January 27 (Reporter Li Yang) French pharmaceutical company Sanofi confirmed on the 27th that the company will assist in the production of the new crown vaccine jointly developed by Pfizer in the United States and BioNTech in Germany, and plans to provide 100 million doses to the EU this year.
Sanofi officially confirmed on the 27th that it has reached an agreement with the United States and Germany to assist in the production of Pfizer vaccine. Sanofi will use its own production line and related technologies to assist in the production of Pfizer vaccines. The total production dose this year is initially expected to be 125 million doses, and the first batch of vaccines are ready to be delivered this summer.
Data picture: In January September local time, Cannes, France, the COVID-19 vaccination center in Cannes Palace began to be opened. The picture shows medical staff getting the COVID-19 vaccine at the COVID-19 vaccination center in the Movie Palace.
Sanofi CEO Hudson said that the company plans to provide 100 million doses of Pfizer vaccine to the EU this year to meet the huge demand for new crown vaccines in EU countries. Pfizer said this month that it would cut the number of vaccines provided to EU countries, which caused dissatisfaction with the EU, and France also urged Pfizer to deliver the vaccine on time.
According to media such as French BFM TV, Sanofi assisted in the production of Pfizer vaccines at this stage will mainly focus on filling drugs and packaging. Negotiations on the production of active ingredients of the vaccine are still in progress. Sanofi needs to obtain necessary logistics support and technology transfer.
Sanofi said that the company's own test vaccine is still under development and may not be launched until the end of this year. The test vaccine has insufficient immune response to the elderly and has to postpone its launch. Hudson said that due to the delayed launch of Sanofi's vaccine, the company is now discussing ways to provide help in the fight against the epidemic.
Sanofi France CEO Boguilo said that to return to normal life, as many people as possible must be vaccinated. Therefore, solidarity efforts are needed in vaccine production, and Sanofi has the production capacity and expertise.
The vaccination work in France is still facing a vaccine supply gap. France's Ministry of Health revealed that by the end of March, France will only receive 4.6 million doses of AstraZeneca vaccine, rather than the approximately 16 million doses originally planned. This means that France's future vaccination progress will be affected as a result. (End)
Source: China News Network
